Search

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…

Read more

All-encompassing meeting on ALL highly rated by participants

Almost 200 delegates from over 30 countries benefitted from stimulating and excellent discussions about Acute Lymphoblastic Leukemia (ALL) at the EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia on April 12-14, 2018 in…

Read more

Two genes cooperate to trigger leukemia development

Congratulations to the international group of researchers led by HemaSphere Editor-in-Chief Prof.

Read more

2018’s Sjöberg Prize awarded for unique treatment that cures a once fatal cancer

Dr. Zhu Chen, Dr. Anne Dejean and Dr. Hugues de Thé will be awarded the Sjöberg Prize 2018 for their work on how acute promyelocytic leukemia (APL) could be cured based on arsenic and retinoic acid.

Read more

HARMONY Alliance: 2nd General Assembly, October 23-24, 2017

The 2nd HARMONY General Assembly is organised from 23-24 October 2017 at Bayer in Berlin. The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 51 partners.

Read more

HARMONY: Innovative Medicines Initiative approves € 40 million project for better care of patients with hematologic malignancies

HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS)…

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Killer antibodies against AML

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more